Compare AMPH & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMPH | INBX |
|---|---|---|
| Founded | 1996 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 971.8M | 999.7M |
| IPO Year | 2005 | 2024 |
| Metric | AMPH | INBX |
|---|---|---|
| Price | $18.18 | $100.93 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 3 |
| Target Price | $28.38 | ★ $150.00 |
| AVG Volume (30 Days) | ★ 644.5K | 489.3K |
| Earning Date | 05-07-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $719,887,000.00 | $1,300,000.00 |
| Revenue This Year | $6.90 | N/A |
| Revenue Next Year | $4.64 | N/A |
| P/E Ratio | $130.00 | ★ N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $16.65 | $12.80 |
| 52 Week High | $31.26 | $155.29 |
| Indicator | AMPH | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 40.00 | 45.50 |
| Support Level | $17.03 | $99.20 |
| Resistance Level | $20.08 | $153.14 |
| Average True Range (ATR) | 0.81 | 13.75 |
| MACD | -0.21 | -3.93 |
| Stochastic Oscillator | 19.16 | 8.06 |
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.